Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Dapagliflozin reduced the primary composite outcome (sustained 50% eGFR decline, ESKD, or death from renal or cardiovascular causes) by 39% compared to placebo [47]
When to Seek Medical Advice Patients should contact their healthcare provider if they experience: Severe, persistent fatigue not improving with adequate nutrition and rest Inability to maintain adequate protein or caloric intake due to gastrointestinal side effects Signs of hypoglycemia (especially in patients taking insulin or sulfonylureas) Symptoms suggesting thyroid dysfunction Severe abdominal pain, especially if radiating to the back (possible pancreatitis) Right upper quadrant pain, fever, or jaundice (possible gallbladder disease) Persistent vomiting or signs of dehydration Concerns about excessive weight loss that should be evaluated individually These situations warrant clinical evaluation to distinguish normal treatment effects from complications requiring intervention
Alcohol interacts with GLP-1 medications in several ways
NSL literature pointer PMID 18978503 L-Carnitine laboratory index [PMID: 18978503] National Science Labs indexing note for PMID 18978503: review the PubMed methods, models, and limitations before citing
US$ 28.81
US$ 26.07
US$ 21.37
